surmount 1 tirzepatide SURPASS to SURMOUNT: The Trials To Know SURMOUNT-1 Trial Summary: What Tirzepatide

A randomized controlled trial using a fractional factorial design showed that compared with placebo, the combined supplementation with riboflavin (3 mg/day) and niacin (40 mg/day) for five to six years reduced the prevalence of nuclear cataract but increased the progression of posterior subcapsular cataracts in population affected by multiple nutrient deficiency living in rural China (38)

The Right Starting Point The trial data is compelling

Images are from the abstract, with the final image being from the original BELIEVE publication showing the 48 week data (rather than the 72)

10.1111/j.1365-2613.2010.00758.x 232 TakaseK.McCullochP